ABSTRACT: Background. Oropharyngeal cancers are increasingly associated with human papillomavirus (HPV). Little is known about the experience of patients receiving this diagnosis. Methods. Semistructured interviews were conducted with ten survivors of HPV-related oropharyngeal cancer. The interviews were transcribed, and recurring themes were identified. Results. Physicians were a trusted source of information regarding HPV. Framing the diagnosis in terms of prognosis resonated with patients. The uncertainty about transmission, latency, and communicability colored the dialogue about HPV. Despite some understanding of prevalence and transmission, patients worried about their partner's risk.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) arising in the setting of high-risk human papillomavirus (HPV), specifically in the oropharynx, is the fastest growing subset of patients with head and neck cancer in the United States. 1 At least half of oropharyngeal cancers diagnosed in the United States are likely attributable to HPV infection, and this number is expected to rise. 2 HPV is a sexually transmitted pathogen, but its natural history and the time course from infection to cancer are poorly understood. 3, 4 Patients with HPV-related oropharyngeal cancer have an improved prognosis following treatment, and there is growing interest in further understanding this cohort of patients with head and neck cancer.
All oropharyngeal tumors should be tested for HPV, given the prognostic implication. 5 However, the impact on patients of the timing, framing, and depth of physician discussion about HPV is not known. Currently, HPV status does not affect treatment decisions, but physicians should discuss the role of HPV, like other risk factors such as tobacco and alcohol, in the development of HNSCC in the spirit of full disclosure. 6 Yet, HPV infection is a complicated concept that requires a substantial time investment on the part of physicians for a detailed explanation that results in adequate patient comprehension. Given the gravity of the HNSCC diagnosis, questions about HPV may be overshadowed by conversations about cancer and its treatment. Moreover, doctors specializing in head and neck cancer may not be familiar with disclosing an HPV diagnosis and counseling patients about sexually transmitted diseases and, as a result, they may feel ill-equipped to answer questions about HPV and the ramifications of this aspect of the diagnosis.
HPV has only recently been associated with HNSCC, and the psychologic impact of its diagnosis in these patients has not been well studied. The consequence of disclosing to a patient that his or her cancer is thought to arise from a sexually transmitted disease carries the potential for confusion, stigma, and anxiety. Although there are important differences between uterine cervical HPV and oropharyngeal HPV, prior studies evaluating the psychosocial sequelae of a diagnosis of HPV during cervical cancer screening have found that women receiving this diagnosis reported feelings of anger, depression, isolation, shame, and guilt. [7] [8] [9] Physicians can play an important role in alleviating some of the negative emotions about an HPV diagnosis with education and receptiveness to further questions and discussions. 10 In a study of women with HPV-related cervical dysplasia, patients' fear of cancer was not proportional to the stage of their dysplasia but was rather determined by a lack of knowledge about their condition. The authors noted that awareness of the patients' perspective allows providers to be empathic in addressing women's fears and their need for additional information. 11 These studies have highlighted the importance of understanding the distress arising from an HPV-related diagnosis and the utility of systematic implementation of educational efforts to alleviate patients' anxiety. 12, 13 Few studies have examined men's reactions to an HPV diagnosis or assessed their knowledge about this common viral pathogen. In a study surveying quality of life in men diagnosed with anogenital warts, men expressed concern about contagiousness and showed inadequate knowledge about their diagnosis. 14, 15 Studies in college students have generally found low levels of knowledge about HPV infection in male participants. 16 In a survey of men who have sex with men (MSM) treated at a sexually transmitted disease (STD) clinic, men who knew someone diagnosed with HPV were knowledgeable of transmission, but overall most patients were unaware of HPV risk or potential modes of transmission. 17 Given the male predominance of HPV-related oropharyngeal cancer and the dearth of data on the potential difficulty in disclosing and explaining this diagnosis to men, additional research is needed. For this reason, we focused on men in this study.
The objective of this pilot study was to increase our understanding of patients' experiences with a diagnosis of HPV-related oropharyngeal cancer by exploring the communication, comprehension, and psychologic impact of the diagnosis.
MATERIALS AND METHODS
As part of a larger study of quality of life and functional outcomes following treatment in male and female survivors of HPV-related oropharyngeal cancer, we conducted a qualitative assessment of communication about, patient reaction to, and psychologic consequences of an HPV HNSCC diagnosis. The larger study remains open at this time. We conducted semi-structured interviews within a single National Cancer Institute-designated comprehensive cancer center. The research protocol was approved by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center (MSKCC).
An interview transcript was developed by a multidisciplinary team of oncologists and behavioral psychologists based on a thorough review of the published literature on HPV in general and HPV in the context of cancer, specifically focusing on communication, knowledge, and psychosexual consequences of the diagnosis. The semistructured interview included open-ended questions in four domains: (1) communication about HPV, (2) knowledge about HPV, (3) psychologic reaction to a diagnosis of HPV and (4) sexual impact of being diagnosed with HPV (Table 1) . Participants were able to independently interpret the questions and answer freely in their own words.
All patients were screened during routine outpatient follow-up visits to assess eligibility for the larger study (age >18 years, fluent in English, pathologic confirmation of an oropharyngeal squamous cell carcinoma, HPV status of tumor known or specimen available for HPV testing, between 1 and 5 years from treatment completion, treatment completed at MSKCC, and no evidence of disease). Patients who consented and agreed to participate in the larger study were then screened for eligibility for this secondary arm of the study. Although initially open to both male and female participants, given the preponderance of male patients with this diagnosis seen in clinics, only male patients were ultimately asked to participate in this qualitative study.
A study investigator described the study goals and obtained informed consent. Given the pilot nature of this aim, we decided a priori to complete 10 interviews. This number represents an adequate number to achieve saturation if the group examined is relatively homogeneous. 18 A trained research study assistant completed the interviews. These interviews were conducted in a private interviewing space and were audiotaped. The recordings were thereafter transcribed verbatim.
Transcripts were analyzed for general themes. A multidisciplinary team of reviewers consisting of a medical oncologist, a surgical oncologist, and a behavioral scientist independently read and analyzed each of the transcripts. The distinct domains of the interview guide provided the structure and framework for these analyses. Each reviewer's analytic process involved drawing general conclusions from specific statements in each domain from the interviews and identifying key quotes to support these conclusions. [19] [20] [21] [22] For cases in which there was a discrepancy in interpretation, the 3 reviewers met in person to discuss the differences and reached a consensus analysis. The reviewers then identified recurring thematic concepts and patterns across the interview domains and ultimately reached consensus at an in-person meeting regarding overarching key themes across all 10 interviews.
Two multiple-choice questions were developed by the investigators using clinical guidance from behavioral scientists and prior research to explore patients' information sources about HPV and their emotional reactions to the HPV diagnosis were also included in the interviews. Results from these questions were summed and tabulated.
In response to requests from study participants for a cohesive, patient-oriented summary of current knowledge about HPV in head and neck cancer, we created a paperbased patient educational pamphlet. Content was derived from the interviews, directly from patients' unanswered questions, as well as from recognized informational gaps and misconceptions. The educational pamphlet was reviewed, edited, and approved by the Committee on Patient Educational Materials at MSKCC (Appendix A).
RESULTS

Description of study sample
The first 10 men who were eligible and agreeable to participate in this aim of the study were interviewed. The median age at diagnosis was 57 years (range, 42-63 years). All patients had been diagnosed with and treated for stage III or stage IV HPV-positive oropharyngeal squamous cell carcinoma. None had evidence of disease at the time of the study interview, with a median follow-up of 22.5 months (range, 16-43 months) from treatment completion. Primary treatment included concurrent chemotherapy and radiation in 9 patients and surgery with adjuvant radiation in 1 patient. At the time of the interview, all 10 men were being followed by both a head and neck surgeon and a radiation oncologist, and 9 of the 10 were also followed by a medical oncologist. Six participants were treated on a therapeutic study protocol. All of the participants were white. Six participants were married, 2 were unmarried in monogamous relationships, and 2 reported being single. According to census data from 2000, 7 of 9 study participants (78%) lived in a zip code with a median income above the national average. Further, 5 participants' zip codes (56%) have median incomes that are also above the mean of the fourth quintile of national incomes. Median income data were not available for 1 participant's zip code. 23 All 10 participants were employed at the time of the survey. Seven participants had never smoked and 3 were former smokers. Two patients reported no alcohol use; 5 reported drinking less than a single alcoholic beverage daily; and 3 consumed more than 1 drink daily.
Disclosing the diagnosis
All participants reported that the diagnosis of an HPV-related tumor was disclosed before the onset of their initial treatments. However, HPV was often overshadowed by broader conversations about the cancer itself. HPV was discussed within the context of an improved oncologic prognosis, which generated an encouraging response in participants.
"Well, it was discussed how it was obtained and that it would be more favorable for me if I had [HPV] as opposed to not having it, and that was. . .sufficient. I had it and I had to deal with. . .what was the cause of it."
Beyond prognosis, the content of the discussion regarding HPV varied greatly based on both patient interest and physician delivery. 
Relationships with clinicians
All participants reported that physicians were their primary source of information about HPV. Although they indicated a high overall level of satisfaction with their doctors' handling of the conversation about HPV, some participants felt that they had questions that remained unasked and unanswered.
"I don't think that [doctors] gave enough information. I think they gave the information that they want to be able to give. They want to give you as much good news as possible, but no one ever discussed anything likemaybe you want to find out or contact or what the. . .sexual ramifications are. . .how could it affect you?"
Reasons reported for not asking further questions included patients' perceptions about: (1) physician time constraints, (2) limited physician knowledge about HPV, and (3) patient or physician discomfort discussing HPV.
"You know, I think that [HPV is not discussed] for many reasons, whether [doctors] feel that it's uncomfortable to discuss with you and your spouse if you're married as I am. . . Somebody's uncomfortable. I'm not uncomfortable talking about it. But I can imagine some people are."
Sources of additional information
Since most patients received a diagnosis of HPV at the time of their cancer diagnosis, they reported that most independent information gathering about HPV took place between diagnosis and the onset of treatment. Once treatment began, interest in learning more about HPV waned.
"Once I started treatment, I ceased any research. I became sick very quickly and, frankly, it was upsetting to read all these things, and I got. . .you know, I was angry at myself, as silly as that may seem. But I was." Not all participants sought additional information; one participant avoided any and all HPV-related information, whereas another had little to no interest in learning about HPV beyond its immediate relationship with his cancer. For the eight participants who did seek out HPV-specific information, the Internet was by far their most common source. In fact, all patients interested in learning about HPV reported using the Internet to some degree to help fill the gaps in their understanding. Participants indicated that although a great deal of information was available on the Internet, it was not patient-centric. Further, many patients had difficulty navigating and comprehending the information they found on the Internet, and several also expressed concerns about its reliability.
"If you go on the search engine and put 'head and neck cancer and HPV,' you'll get a. . .a drop down of various articles. Getting into something which is substantive and understandable from a layman's standpoint can take a little more digging."
Many participants reported attempting to synthesize what they learned from the Internet and confirming its veracity with their physicians. Results from multiple-choice responses regarding patients' sources of HPV information are presented in Table 2 .
Misconceptions, knowledge gaps, and concerns
All participants understood that: (1) HPV is a sexually transmitted pathogen, (2) HPV is widely prevalent in the United States, and (3) HPV has a positive prognostic implication in HNSCC. Beyond this, participants' knowledge about HPV varied significantly. This variation was attributed to patients' interest in learning about HPV, time spent researching the topic, and comprehension of, and trust in, online information resources.
"My doctors all explained how you contracted it and. . .the nature of it. It was. . .simple enough. It wasn't something we dwelled on that extensively. I had no desire to dwell on it that much. I had other things coming my way, such as the radiation and the rest of my treatment."
Few participants understood the mechanism of HPV transmission. For this reason, many unanswered questions concerned viral transmissibility and latency, relating to both the source of original infection and the potential consequences for participants' current or future partner(s).
"Can you get it. . .You know, just from kissing someone? You know, from saliva, from mouth-to-mouth. Possibly, you know, but then, you know, I don't know."
Psychologic impact from HPV
Three participants indicated that they felt a sense of stigma or embarrassment associated with their diagnosis of a sexually transmitted disease.
". . .My wife's got an oncologist. As soon as she [wife's oncologist] heard that I had [HPV], she thought that I was having some like crazy wild, you know, gay party lifestyle that my wife didn't know about."
Further, the belief that antecedent behaviors may have indirectly led to the development of cancer resulted, for some, in anger, sadness, or helplessness.
"Obviously the prospect of this being sexually transmitted can be somewhat embarrassing to think about that. That, you know, something I did when I was single 25, 30 years ago came back to haunt me. You know, was all-inall embarrassing to say the least." "I wanted to find out who the heck it was who gave it to me. A little bit of anger, I want to find out. . .. However, after I thought about it for a while, like I said, there wasn't anything I can do about it, finding out, but in thinking about it, I had an idea. You know, I narrowed it down to a few."
Results from a multiple-choice worksheet on patients' emotional responses to learning about HPV's role in their cancer are presented in Table 3 . When assessing their emotional responses, participants struggled to separate the sentiments associated with HPV from those related to their cancer diagnosis. About half of the participants indicated that the cancer itself occasionally or always overshadowed the impact of HPV.
"HPV doesn't bother me at all and maybe it should. But I think most modern day people deal with sexually transmitted diseases as a nuisance when they get them. If they get them, they are treated, and that's it. So I was frankly more concerned about the cancer than I was about the HPV. I had heard of HPV alright, but you know, not any sort of dramatic terms as a killer. The one thing that moved me was the cancer."
Relief and optimism were common emotional responses to the improved prognosis implied by HPV-related HNSCC.
"Actually, I felt relieved because in that I felt that it enhanced my chances of recovery. So I wasn't. . ., I wasn't that upset with it I guess." "Once I knew that they were looking for [HPV] and that it would be beneficial for me, I hoped that I would have it. That's. . .that's all. And from that point, I was really trying to deal with getting through the cancer and the treatment and what was in store for me. The HPV then became. . . It was relevant, but it was secondary."
Impact on intimacy
The discomfort regarding HPV transmission and latency persisted long after the completion of treatment in the study cohort. Of eight participants who discussed the impact of their diagnosis on sexual relationships (1 was not sexually active, another did not want to discuss this topic), five had decreases in intimacy that were at least partly related to their HPV diagnosis, mostly due to transmission-related fears. Some participants attributed decreases in intimacy to treatment-related effects rather than (or in addition to) HPV. "During treatment, of course when I had all the sores, and I developed thrush, that was a different story. I gotta. . . I gotta basically say I was an outcast, you know. There would be no kissing."
Although half of these eight men reported that they did not significantly alter their sexual practices as a direct result of HPV, three men completely eliminated oral sex or deep kissing, even with long-term partners.
"You got burned on the stove, you don't want to touch the stove again. You know, it's like that. Even if you know the stove is off, you're still a little scared of the stove."
Four of the men were concerned about potentially infecting a partner with HPV, and one even expressed concerns about HPV reinfection. "I'm not concerned that I'm giving it to my wife at all, but I haven't had oral sex with my wife, and it's in the back of . . . I don't want to say in the back of my mind.
It's in the forefront of my mind, you know. Would I get it again? Did I get it from her to begin with?"
Need for better dissemination of information
Although patients have different information requirements, all but one of the participants requested more information about HPV. Many remarked that a cohesive, comprehensive, and trusted resource would be valuable, and some patients specifically requested an informational pamphlet or handout.
"A simple handout that you guys could do in a few minutes may make a world of difference in easing someone's mind or making them very nervous, but at least it's getting the information out."
As a result, the study team, in conjunction with the MSKCC Committee on Patient Educational Materials, developed a paper-based pamphlet containing information about HPV and its role in head and neck cancer. This handout has been written on a Flesch-Kincaid seventhgrade reading level and targets the general population of head and neck cancer patients who are interested in HPV and have relevant questions (Appendix A).
DISCUSSION
This qualitative study of men with HPV-related head and neck cancer provides important insight about the ways in which patients learn about and understand their diagnosis, and the impact it has on their psychosexual health. Our findings suggest that patients rely on their physicians for information about HPV but are generally looking for more information than they typically receive. Participants in this study learned about HPV at the time of their cancer diagnosis, and those with additional questions used the pretreatment period to acquire more information.
The men we interviewed understood and were encouraged by the positive prognostic implication of an HPV diagnosis, which is readily discussed by physicians. However, the sexual transmission of HPV was an area of confusion and concern. Specifically, the mechanism and likelihood of communicability, along with uncertainty regarding viral latency, were frequently cited as unanswered questions. These topics were less likely to be addressed by physicians, potentially due to their own discomfort or lack of experience discussing sexually transmitted illnesses. 24 Unlike gynecologists or primary care physicians, HPV and sexual function constitute new territory for head and neck cancer providers. It is possible that as these conversations become more frequent in the context of head and neck cancer, physicians will improve the content and delivery of education about HPV in response to patients' reactions and questions. In prior studies of women with positive HPV results, perceived poor communication about the sexual nature of HPV was a source of anxiety and frustration. 9, 10 While discussing HPV in the context of an improved oncologic prognosis reassures patients and is more comfortable ground for physicians, further efforts are needed to adequately address the sexual implications of HPV.
Our study specifically addressed issues about sexual intimacy following diagnosis and treatment of an HPV-positive HNSCC. There appeared to be 2 main etiologies of changes in sexual practice. Some participants continued to have decreased sexual desire or enjoyment, which was directly attributable to the stigmata of their cancer treatments. This is consistent with prior reports in cancer survivors who reported long-term sexual dysfunction following treatment. 25, 26 The other reason for altered sexual practice was the HPV diagnosis itself. Whereas several men in our study were concerned about infecting their partners, one worried about reinfection. Women diagnosed with HPV on cervical cancer screening reported similar sexual dysfunction (decreased sexual enjoyment, drive, and frequency). 10, 27 Related data from the cervical cancer literature suggest that a better understanding of patients' responses to HPV may help guide interventions to diminish harmful psychosocial and interpersonal reactions while also promoting healthy sexual activity. 28 Similar studies are warranted in patients diagnosed with HPVrelated head and neck cancer to examine the negative potential impact of an HPV diagnosis on sexual intimacy.
Some participants expressed feelings of shame related to the sexually transmitted nature of HPV. Based on prior literature, we would have expected prominent stigma, shame, and anxiety related to a diagnosis of HPV. 9 Prior studies have found that women who had knowledge about both the sexually transmitted nature of HPV and the high prevalence of the virus in the general population experienced far less stigma and shame than did women who did not understand the prevalence or etiology of the disease. [29] [30] [31] All of the men in this study expressed an understanding of both aspects about HPV; this fact, combined with the potential difference in perspective between genders, may explain our findings. In addition, we interviewed patients several years after their diagnosis, allowing ample time for reflection and evolving emotional responses. Sharing information regarding the prevalence of HPV infection and its transmissibility may help to mitigate the stigma and shame associated with the diagnosis of HPV-related oropharyngeal cancer.
Patients' persistent questions about HPV, coupled with their reliance on doctors for answers given the inadequacy of the Internet and other resources, suggest that clinicians need to educate and inform their patients more effectively. Another strategy to improve HPV understanding is utilizing professional societies such as the American Society of Clinical Oncology (ASCO), the American Head and Neck Society (AHNS), or American Cancer Society (ACS) for information dissemination. In prior studies, young women diagnosed with genital HPV demonstrated immediate understanding of information about HPV but poor longerterm recall, suggesting that educational interventions should be repeated and reinforced. 32 These findings highlight the need for clinicians to provide continuing educational opportunities and to facilitate answers to patients' difficult (and sometimes unasked) questions, many of which may be challenging to address adequately. Physicians' perceived comfort level and knowledge are seen as potential barriers to patients' willingness to broach the topic of HPV; although our participants did not explicitly discuss it, we expect that patients' own discomfort initiating these conversations may also be prominent. In a study of female college students with genital HPV infection, ancillary health providers such as nurses provided counseling and education more regularly than did physicians; the implications for potential alternative sources of counseling and education in the HNSCC population deserve further attention. 33 As a result of our findings and in direct response to participant requests, we have developed an educational pamphlet that is designed to provide patients with the information necessary for patients to understand their HPV diagnosis and its implications in the context of head and neck cancer. Further, it can serve as a springboard for conversations about HPV between patients and their clinicians, both of whom may be uncomfortable discussing HPV and issues related to sexual transmission and psychosexual ramifications. Although a printed handout does not supplant the doctor-patient relationship, we anticipate that it can complement and facilitate interpersonal education and counseling.
This study has several limitations. With a small number of participants from a single institution, the generalizability of our findings may be limited. While interviewing members of the relatively homogeneous population seen in our clinics facilitated study accrual and completion, it also limits our ability to extrapolate findings to other patient populations. Specifically, our participants were all white men mostly from a higher socioeconomic background. In addition, given that all patients knew about HPV from the time of their diagnosis, this study does not specifically address the needs of patients who have not yet had an HPV diagnosis disclosed or of HPV-negative patients with HNSCC who may have questions about HPV. Although the educational handout we created was developed in response to a perceived need, it has not yet been subjected to rigorous testing regarding comprehensibility, utility, or effectiveness in communicating important information.
CONCLUSIONS
This pilot study provides preliminary data concerning patients' psychologic and sexual reactions to a diagnosis of HPV-related head and neck cancer. Physicians remain a trusted source of information regarding HPV, but questions frequently persist, and ancillary resources such as the Internet do not provide adequate answers. Although patients often focus on their diagnosis of cancer rather than that of HPV, expressing relief about the positive impact of HPV on prognosis, their emotional reactions to HPV disclosure are diverse and occasionally distressing. An educational resource further explaining HPV-related head and neck cancer is needed and, as a result, we have developed a patient-centered informational pamphlet. Human Papilloma Virus (HPV) is a virus that can infect the skin and the mucosa (lining) of the mouth, throat, genitals, and anal area. Infections with HPV are common. Most people infected with HPV will not have any symptoms, and their immune system will get rid of the HPV infection without any treatment. In some cases, however, HPV can lead to cancer. We do not know why some people are able to get rid of their HPV infection before it causes cancer, and why others cannot. Are there different types of HPV?
Yes, and different types of HPV can cause different kinds of infections. Some types of HPV cause warts on the skin, mouth, or genitals. There are other types of HPV that can cause cancer. These are known as high-risk types. The most common type of cancer caused by HPV is cervical cancer. This is why women get Pap smears, which include checking for HPV. High-risk HPV can also cause head and neck cancer in both men and women. How is HPV spread?
HPV can be spread when the skin or mucosa comes into contact with an infected person's skin or mucosa. For high-risk HPV types, this usually happens through sexual contact. Although we do not know for sure, we think most HPV infections that cause head and neck cancer are spread through oral sex, and possibly by ''open mouth" kissing. Because HPV is so common, it is hard to know exactly when the infection started or who passed it on. How does HPV cause head and neck cancer?
We don't know for sure. Most people who are exposed to high-risk HPV will not get cancer. However, some people are unable to get rid of their HPV infection, and the virus creates damage that eventually causes a tumor to grow. It often takes many years for the HPV-infected cells to become cancerous. We cannot predict whose infection will disappear and who will develop cancer. Most head and neck cancers that happen as a result of HPV infection occur in the part of the throat that includes the base of the tongue and the tonsils. How do I know if HPV caused my cancer?
When a head and neck cancer is diagnosed, the tumor itself can be tested for HPV. This is currently the only way to test if a cancer in the throat is related to HPV. Does my HPV status change my treatment or my chance of being cured?
In general, patients with HPV-positive head and neck cancer have better outcomes than patients with head and neck cancer that is not related to HPV. However, both types of cancers are currently treated in the same way, irrespective of whether they are caused by/related to HPV. Treatment decisions are made based on the size and location of the tumor, the stage of the disease, the overall health of the patient, and the wishes of the patient. Researchers are studying if cancer treatments should be changed based on whether HPV is or is not involved.
Am I contagious?
HPV is not spread through routine physical contact (ie, touching, kissing on the cheek or lips); however, HPV is a contagious virus that is extremely common among sexually active people. This means if you have been diagnosed with HPV it is likely that your sexual partners have also been exposed. Since most people get rid of the infection on their own, the chance of your partner getting an HPV-related cancer is very low, even when exposed to high-risk types. If you have cancer caused by HPV, there are no special precautions or specific changes in your sexual practices that are currently recommended. Should my partner be screened for HPV?
If your partner is female, she should follow normal women's health guidelines, which include having a routine Pap test. If your partner is male, he does not need any special exams or tests because there is no routine or standard HPV screening offered for men. In addition, there is no effective screening test for head and neck cancer. No other special precautions are necessary, because your partner's chance of getting cancer as a result of HPV infection is extremely low. Your partner should discuss any specific symptoms or concerns with his or her doctor.
What about tobacco and alcohol?
People who abuse alcohol or tobacco are more likely to get head and neck cancer. However, HPV-related cancers can develop irrespective of whether you do or do not drink alcohol or use tobacco products. Patients with cancer who do not use tobacco or alcohol live longer and are less likely to develop new cancers. For this reason, all patients with head and neck cancer should quit using tobacco and should minimize their use of alcohol. If you need help changing these habits, MSKCC can help you. Ask your doctor or nurse for more information about our programs, or call the Counseling Center at (646) 888-0100. Can HPV be cured?
At this time there is no way to cure HPV. Most people infected with HPV will get rid of the infection without any treatment. Can I get another cancer from HPV?
The risk of getting a second cancer from HPV is low, but your doctors will continue to examine you regularly. Be sure to tell your doctors about any new symptoms or concerns. Should I get the HPV vaccine? Should my family get the vaccine?
The HPV vaccine is currently recommended for all boys and girls between the ages of 11 to 14, before sexual exposure. The main goal of the vaccine is to prevent genital warts and cervical cancer. We think the vaccine might also protect against HPV-related head and neck cancer; however, this has not yet been proven. The vaccine is effective only if given before HPV infections occur. As a result, there is no proven benefit from the vaccine for people with HPV-related cancer, or for their partners. Where can I find more information?
The best place to get more information is from your doctors. There is a lot of information about HPV and cancer on the Internet and some of it is confusing and inaccurate. We recommend the American Cancer Society website, www.cancer.org. Information is also available from the organization Support for People with Oral and Head and Neck Cancer (SPOHNC), www.spohnc.org.
You can also visit the Memorial Sloan-Kettering Cancer Center Library online at http://library.mskcc.org. Do not hesitate to contact reference staff at (212) 639-7439 or by using the ''Ask-a-Librarian" email link (http://library.mskcc.org/scripts/ portal/forms/ask_librarian.pl). V C 2012 Memorial Sloan-Kettering Cancer Center
